{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2019"],"condition":["Pazienti affetti da tumore del colon-retto metastatico in progressione dopo =2 linee di trattamento","Gastrointestinal cancer metastatic","Patients with mCRC progressed after =2 lines of standard treatment"],"disease":["Pazienti Affetti Da Tumore Del Colon-retto Metastatico In Progressione Dopo =2 Linee Di Trattamento","Patients With Mcrc Progressed After =2 Lines Of Standard Treatment","Gastrointestinal Cancer Metastatic"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2538920"],"location":["Italy"],"study_start_month":["7"],"keyword":["CABOZANTINIB"],"repository":["ECRIN MDR"],"study_status":["Ongoing"],"additional_accession":[]},"is_claimable":false,"name":"A phase II trial with cabozantinib in patients with metastatic colorectal cancer, after previous treatment (mCRC).","description":"Primary objectives: To determine the anti-tumour activity of cabozantinib (evaluated as the number of patients that are free of progression at 16 weeks since the start of treatment) in chemorefractory patients with mCRC, after progression from =2 lines of treatment.\nPrimary endpoints: Progression Free Survival (PFS) rate at 16 weeks: the rate of patients who have not experienced disease progression or death for any cause at 16 weeks.","dates":{"creation":"2019-07-15"},"accession":"2538920","cross_references":{"EU Clinical Trials Register":["2019-000674-28"]}}